Literature DB >> 22349292

The effects of membrane cholesterol and simvastatin on red blood cell deformability and ATP release.

Alison M Forsyth1, Susanne Braunmüller, Jiandi Wan, Thomas Franke, Howard A Stone.   

Abstract

It is known that deformation of red blood cells (RBCs) is linked to ATP release from the cells. Further, membrane cholesterol has been shown to alter properties of the cell membrane such as fluidity and bending stiffness. Membrane cholesterol content is increased in some cardiovascular diseases, for example, in individuals with acute coronary syndromes and chronic stable angina, and therefore, because of the potential clinical relevance, we investigated the influence of altered RBC membrane cholesterol levels on ATP release. Because of the correlation between statins and reduced membrane cholesterol in vivo, we also investigated the effects of simvastatin on RBC deformation and ATP release. We found that reducing membrane cholesterol increases cell deformability and ATP release. We also found that simvastatin increases deformability by acting directly on the membrane in the absence of the liver, and that ATP release was increased for cells with enriched cholesterol after treatment with simvastatin.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349292     DOI: 10.1016/j.mvr.2012.02.004

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  22 in total

1.  Cholesterol Regulates Monocyte Rolling through CD44 Distribution.

Authors:  Amit K Saha; Pawel Osmulski; Shatha F Dallo; Maria Gaczynska; Tim H-M Huang; Anand K Ramasubramanian
Journal:  Biophys J       Date:  2017-04-11       Impact factor: 4.033

Review 2.  Biomechanical properties of red blood cells in health and disease towards microfluidics.

Authors:  Giovanna Tomaiuolo
Journal:  Biomicrofluidics       Date:  2014-09-17       Impact factor: 2.800

3.  Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.

Authors:  Peer Wf Karmaus; Min Shi; Shira Perl; Angélique Biancotto; Julián Candia; Foo Cheung; Yuri Kotliarov; Neal Young; Michael B Fessler
Journal:  JCI Insight       Date:  2019-11-01

Review 4.  Influence of Erythrocyte Membrane Stability in Atherosclerosis.

Authors:  Mario da Silva Garrote-Filho; Morun Bernardino-Neto; Nilson Penha-Silva
Journal:  Curr Atheroscler Rep       Date:  2017-04       Impact factor: 5.113

5.  Atorvastatin treatment softens human red blood cells: an optical tweezers study.

Authors:  Vahid Sheikh-Hasani; Mehrad Babaei; Ali Azadbakht; Hamidreza Pazoki-Toroudi; Alireza Mashaghi; Ali Akbar Moosavi-Movahedi; Seyed Nader Seyed Reihani
Journal:  Biomed Opt Express       Date:  2018-02-20       Impact factor: 3.732

6.  Hemolysis is a primary ATP-release mechanism in human erythrocytes.

Authors:  Jacek Sikora; Sergei N Orlov; Kishio Furuya; Ryszard Grygorczyk
Journal:  Blood       Date:  2014-08-05       Impact factor: 22.113

7.  Simvastatin and GGTI-2133, a geranylgeranyl transferase inhibitor, increase erythrocyte deformability but reduce low O(2) tension-induced ATP release.

Authors:  K M Clapp; M L Ellsworth; R S Sprague; A H Stephenson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-18       Impact factor: 4.733

Review 8.  Blood cells: an historical account of the roles of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-08-11       Impact factor: 3.765

9.  Effects of simvastatin and atorvastatin on biochemical and hematological markers in patients with risk of cardiovascular diseases.

Authors:  Jian-Bo Xian-Yu; Jia-Fu Feng; Yu-Chun Chen; Yu-Wei Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  RBC-NOS-dependent S-nitrosylation of cytoskeletal proteins improves RBC deformability.

Authors:  Marijke Grau; Sebastian Pauly; Jamal Ali; Katja Walpurgis; Mario Thevis; Wilhelm Bloch; Frank Suhr
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.